Despite this mechanistic similarity, TBL1XR1-RARB-positive APL demonstrates intrinsic resistance to standard differentiating agents, including ATRA, ATO, and the synthetic retinoid tamibarotene (6, 11, 14, 25). Here, TBL1XR1 is linked to acute promyelocytic leukemia.